Cargando…

Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms

INTRODUCTION: Infantile spasms (IS) is a rare and devastating form of early childhood epilepsy. Two drugs are approved in the United States for treatment of IS, H.P. Acthar(®) Gel (repository corticotropin injection, RCI) and Sabril(®) (vigabatrin). Given real-world variation in treatment of patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Gold, Laura S, Nazareth, Tara A, Yu, Tzy-Chyi, Fry, Keith R, Mahler, Nancy Ho, Rava, Andrew, Waltrip II, Royce W, Hansen, Ryan N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997416/
https://www.ncbi.nlm.nih.gov/pubmed/32099512
http://dx.doi.org/10.2147/PHMT.S222010
_version_ 1783493693088464896
author Gold, Laura S
Nazareth, Tara A
Yu, Tzy-Chyi
Fry, Keith R
Mahler, Nancy Ho
Rava, Andrew
Waltrip II, Royce W
Hansen, Ryan N
author_facet Gold, Laura S
Nazareth, Tara A
Yu, Tzy-Chyi
Fry, Keith R
Mahler, Nancy Ho
Rava, Andrew
Waltrip II, Royce W
Hansen, Ryan N
author_sort Gold, Laura S
collection PubMed
description INTRODUCTION: Infantile spasms (IS) is a rare and devastating form of early childhood epilepsy. Two drugs are approved in the United States for treatment of IS, H.P. Acthar(®) Gel (repository corticotropin injection, RCI) and Sabril(®) (vigabatrin). Given real-world variation in treatment of patients with IS, this study characterized treatment patterns with IS medications and determined all-cause health care resource utilization (HCRU) during the 90 days before initiating therapy with RCI in patients with IS. MATERIALS AND METHODS: Truven Health MarketScan(®) Research Databases were used to identify commercially insured US patients <2 years of age at RCI initiation with an IS diagnosis, per label use, from 1/1/07 to 12/31/15; presence of an electroencephalogram following diagnosis was required to assure diagnosis. Diagnosis codes and dispensed IS treatments of interest (drug classes including corticosteroids, vigabatrin, and other antiepileptic drugs [AEDs] excluding vigabatrin) before RCI initiation were evaluated. RESULTS: The 5 most common diagnoses other than IS observed in the study cohort (n=422) were “other convulsions,” “acute upper respiratory infection,” “esophageal reflux,” “epilepsy, unspecified,” and “abnormal involuntary muscle movements.” Among the study cohort, 51.7% received RCI first; 38.9% received 1 drug class and 9.5% received >1 drug class before RCI initiation. Other AEDs were dispensed most often, either alone (31.3%) or with other drug classes (9.3%). Mean HCRU included 11.8 all-cause outpatient visits and 4.5 medications dispensed. Patients who received RCI or corticosteroids as their initial IS treatment had the lowest and second-lowest HCRU. CONCLUSION: In the 90 days before initiating RCI, patients with IS received multiple diagnoses and treatments, characterized by frequent HCRU. Use of RCI first (no prior IS medications) and AEDs first were associated with the lowest and highest HCRU, respectively, across all categories (all-cause outpatient visits, emergency department visits, hospital admissions, prescription medications).
format Online
Article
Text
id pubmed-6997416
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69974162020-02-25 Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms Gold, Laura S Nazareth, Tara A Yu, Tzy-Chyi Fry, Keith R Mahler, Nancy Ho Rava, Andrew Waltrip II, Royce W Hansen, Ryan N Pediatric Health Med Ther Original Research INTRODUCTION: Infantile spasms (IS) is a rare and devastating form of early childhood epilepsy. Two drugs are approved in the United States for treatment of IS, H.P. Acthar(®) Gel (repository corticotropin injection, RCI) and Sabril(®) (vigabatrin). Given real-world variation in treatment of patients with IS, this study characterized treatment patterns with IS medications and determined all-cause health care resource utilization (HCRU) during the 90 days before initiating therapy with RCI in patients with IS. MATERIALS AND METHODS: Truven Health MarketScan(®) Research Databases were used to identify commercially insured US patients <2 years of age at RCI initiation with an IS diagnosis, per label use, from 1/1/07 to 12/31/15; presence of an electroencephalogram following diagnosis was required to assure diagnosis. Diagnosis codes and dispensed IS treatments of interest (drug classes including corticosteroids, vigabatrin, and other antiepileptic drugs [AEDs] excluding vigabatrin) before RCI initiation were evaluated. RESULTS: The 5 most common diagnoses other than IS observed in the study cohort (n=422) were “other convulsions,” “acute upper respiratory infection,” “esophageal reflux,” “epilepsy, unspecified,” and “abnormal involuntary muscle movements.” Among the study cohort, 51.7% received RCI first; 38.9% received 1 drug class and 9.5% received >1 drug class before RCI initiation. Other AEDs were dispensed most often, either alone (31.3%) or with other drug classes (9.3%). Mean HCRU included 11.8 all-cause outpatient visits and 4.5 medications dispensed. Patients who received RCI or corticosteroids as their initial IS treatment had the lowest and second-lowest HCRU. CONCLUSION: In the 90 days before initiating RCI, patients with IS received multiple diagnoses and treatments, characterized by frequent HCRU. Use of RCI first (no prior IS medications) and AEDs first were associated with the lowest and highest HCRU, respectively, across all categories (all-cause outpatient visits, emergency department visits, hospital admissions, prescription medications). Dove 2019-12-31 /pmc/articles/PMC6997416/ /pubmed/32099512 http://dx.doi.org/10.2147/PHMT.S222010 Text en © 2019 Gold et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Gold, Laura S
Nazareth, Tara A
Yu, Tzy-Chyi
Fry, Keith R
Mahler, Nancy Ho
Rava, Andrew
Waltrip II, Royce W
Hansen, Ryan N
Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms
title Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms
title_full Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms
title_fullStr Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms
title_full_unstemmed Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms
title_short Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms
title_sort medication utilization patterns 90 days before initiation of treatment with repository corticotropin injection in patients with infantile spasms
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997416/
https://www.ncbi.nlm.nih.gov/pubmed/32099512
http://dx.doi.org/10.2147/PHMT.S222010
work_keys_str_mv AT goldlauras medicationutilizationpatterns90daysbeforeinitiationoftreatmentwithrepositorycorticotropininjectioninpatientswithinfantilespasms
AT nazarethtaraa medicationutilizationpatterns90daysbeforeinitiationoftreatmentwithrepositorycorticotropininjectioninpatientswithinfantilespasms
AT yutzychyi medicationutilizationpatterns90daysbeforeinitiationoftreatmentwithrepositorycorticotropininjectioninpatientswithinfantilespasms
AT frykeithr medicationutilizationpatterns90daysbeforeinitiationoftreatmentwithrepositorycorticotropininjectioninpatientswithinfantilespasms
AT mahlernancyho medicationutilizationpatterns90daysbeforeinitiationoftreatmentwithrepositorycorticotropininjectioninpatientswithinfantilespasms
AT ravaandrew medicationutilizationpatterns90daysbeforeinitiationoftreatmentwithrepositorycorticotropininjectioninpatientswithinfantilespasms
AT waltripiiroycew medicationutilizationpatterns90daysbeforeinitiationoftreatmentwithrepositorycorticotropininjectioninpatientswithinfantilespasms
AT hansenryann medicationutilizationpatterns90daysbeforeinitiationoftreatmentwithrepositorycorticotropininjectioninpatientswithinfantilespasms